The University of Chicago Header Logo

Connection

Sarosh Rana to Vascular Endothelial Growth Factor Receptor-1

Back to Details
This is a "connection" page, showing publications Sarosh Rana has written about Vascular Endothelial Growth Factor Receptor-1.
Sarosh Rana
Connection Strength
15.647
Vascular Endothelial Growth Factor Receptor-1
  1. Luteolin decreases sFlt-1 and mean arterial pressure in the RUPP animal model of placental ischemia. Placenta. 2026 Aug; 182:150-157.
    View in: PubMed
    Score: 0.874
  2. Placental Biomarker Testing for Evaluation of Suspected Preeclampsia. Clin Chem. 2025 May 02; 71(5):548-558.
    View in: PubMed
    Score: 0.808
  3. Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers. Pregnancy Hypertens. 2025 Mar; 39:101190.
    View in: PubMed
    Score: 0.792
  4. Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025 Apr; 232(4):385.e1-385.e21.
    View in: PubMed
    Score: 0.764
  5. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. Am J Obstet Gynecol MFM. 2021 07; 3(4):100394.
    View in: PubMed
    Score: 0.613
  6. Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. Pregnancy Hypertens. 2021 Mar; 23:97-103.
    View in: PubMed
    Score: 0.595
  7. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2022 02; 226(2S):S1019-S1034.
    View in: PubMed
    Score: 0.590
  8. Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia. Pregnancy Hypertens. 2020 Jul; 21:124-131.
    View in: PubMed
    Score: 0.574
  9. Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension. Pregnancy Hypertens. 2020 Apr; 20:124-130.
    View in: PubMed
    Score: 0.568
  10. Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. Pregnancy Hypertens. 2018 Oct; 14:110-114.
    View in: PubMed
    Score: 0.509
  11. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens. 2018 Jul; 13:100-106.
    View in: PubMed
    Score: 0.499
  12. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy. 2016 Aug; 35(3):330-45.
    View in: PubMed
    Score: 0.430
  13. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS One. 2015; 10(5):e0126815.
    View in: PubMed
    Score: 0.404
  14. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn. 2015 Apr; 35(4):386-93.
    View in: PubMed
    Score: 0.397
  15. Response to Carbillon L et al. letter titled; "The imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsia". Hypertens Pregnancy. 2014 Nov; 33(4):525.
    View in: PubMed
    Score: 0.383
  16. Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. Hypertens Pregnancy. 2014 Nov; 33(4):427-39.
    View in: PubMed
    Score: 0.383
  17. Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1a pathway. FASEB J. 2014 Oct; 28(10):4324-34.
    View in: PubMed
    Score: 0.381
  18. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014 Feb; 63(2):198-202.
    View in: PubMed
    Score: 0.364
  19. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013 May; 32(2):189-201.
    View in: PubMed
    Score: 0.351
  20. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012 Aug; 60(2):451-8.
    View in: PubMed
    Score: 0.332
  21. Angiogenic factors and pregnant woman with new onset seizures. Hypertens Pregnancy. 2012; 31(2):207-10.
    View in: PubMed
    Score: 0.324
  22. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012 Feb 21; 125(7):911-9.
    View in: PubMed
    Score: 0.322
  23. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007 Jul; 50(1):137-42.
    View in: PubMed
    Score: 0.233
  24. Neonatal outcome gains from sFlt-1/PlGF testing in hypertensive disorders of pregnancy: Modeled estimates from real-world data in the US. Pregnancy Hypertens. 2026 Sep; 45:101507.
    View in: PubMed
    Score: 0.221
  25. Serum soluble-fms-like tyrosine kinase 1-to-placental growth factor ratio on Elecsys immunoassay platform predicts preeclampsia with severe features in hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2026 Mar; 234(3):834-855.
    View in: PubMed
    Score: 0.209
  26. Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio. Am J Clin Pathol. 2025 08 26; 164(2):200-206.
    View in: PubMed
    Score: 0.206
  27. Reference Range Determination for the sFlt-1/PlGF Ratio in a Diverse Cohort of Pregnant Women in the United States. J Appl Lab Med. 2025 07 01; 10(4):937-948.
    View in: PubMed
    Score: 0.204
  28. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing. Am J Obstet Gynecol. 2024 09; 231(3):363.e1-363.e11.
    View in: PubMed
    Score: 0.189
  29. Bioflavonoid luteolin prevents sFlt-1 release via HIF-1a inhibition in cultured human placenta. FASEB J. 2023 08; 37(8):e23078.
    View in: PubMed
    Score: 0.179
  30. Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. Pregnancy Hypertens. 2022 Aug; 29:108-115.
    View in: PubMed
    Score: 0.166
  31. Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clin Chem. 2022 06 01; 68(6):771-781.
    View in: PubMed
    Score: 0.165
  32. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022 Mar; 27:42-50.
    View in: PubMed
    Score: 0.160
  33. Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertens. 2021 Dec; 26:121-126.
    View in: PubMed
    Score: 0.158
  34. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center. Pregnancy Hypertens. 2021 Aug; 25:7-11.
    View in: PubMed
    Score: 0.153
  35. Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform. Pregnancy Hypertens. 2018 Jan; 11:66-70.
    View in: PubMed
    Score: 0.121
  36. Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. Sci Total Environ. 2017 Dec 01; 599-600:2175-2181.
    View in: PubMed
    Score: 0.117
  37. Myocardial performance index in hypertensive disorders of pregnancy: The relationship between blood pressures and angiogenic factors. Hypertens Pregnancy. 2017 May; 36(2):161-167.
    View in: PubMed
    Score: 0.115
  38. Angiogenic Proteins: Can These Biomarkers Help to Prevent Maternal Deaths Related to Preeclampsia? Hypertension. 2017 03; 69(3):401-403.
    View in: PubMed
    Score: 0.114
  39. Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1. Pregnancy Hypertens. 2016 Oct; 6(4):313-319.
    View in: PubMed
    Score: 0.109
  40. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. JACC Heart Fail. 2016 05; 4(5):380-8.
    View in: PubMed
    Score: 0.107
  41. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.
    View in: PubMed
    Score: 0.104
  42. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation. 2015 Nov 03; 132(18):1726-33.
    View in: PubMed
    Score: 0.104
  43. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy. 2014 Feb; 33(1):81-92.
    View in: PubMed
    Score: 0.092
  44. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy. 2014 May; 33(2):250-9.
    View in: PubMed
    Score: 0.092
  45. Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):643-50.
    View in: PubMed
    Score: 0.091
  46. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med. 2013 Sep 01; 41(5):511-6.
    View in: PubMed
    Score: 0.090
  47. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One. 2012; 7(10):e48259.
    View in: PubMed
    Score: 0.085
  48. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension. 2012 Feb; 59(2):256-64.
    View in: PubMed
    Score: 0.080
  49. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregnancy. 2012; 31(2):211-7.
    View in: PubMed
    Score: 0.080
  50. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med. 2012 Jul; 25(7):1135-41.
    View in: PubMed
    Score: 0.079
  51. Placental expression of angiogenic factors in Trisomy 13. Am J Obstet Gynecol. 2011 Jun; 204(6):546.e1-4.
    View in: PubMed
    Score: 0.076
  52. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol. 2011 Mar; 204(3):244.e1-12.
    View in: PubMed
    Score: 0.074
  53. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med. 2010 May; 23(5):366-70.
    View in: PubMed
    Score: 0.071
  54. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis. 2008 Jun; 51(6):1029-32.
    View in: PubMed
    Score: 0.062
  55. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007 Feb; 30(2):375-7.
    View in: PubMed
    Score: 0.057
  56. Reply to the letter to the editor: "Machine learning model for predicting preeclampsia-related adverse outcomes". Pregnancy Hypertens. 2026 09; 45:101501.
    View in: PubMed
    Score: 0.055
  57. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid. 2022 Dec; 1(12):EVIDoa2200161.
    View in: PubMed
    Score: 0.043
  58. The additive role of angiogenic markers for women with confirmed preeclampsia. Am J Obstet Gynecol. 2023 05; 228(5):573.e1-573.e11.
    View in: PubMed
    Score: 0.042
  59. Angiogenic factors and prediction for ischemic placental disease in future pregnancies. Pregnancy Hypertens. 2021 Aug; 25:12-17.
    View in: PubMed
    Score: 0.038
  60. Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. Pregnancy Hypertens. 2016 Oct; 6(4):333-339.
    View in: PubMed
    Score: 0.027
  61. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012 May 09; 485(7398):333-8.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.